Dr Armaghani highlights several key advancements in hormone receptor‒positive, HER2-negative breast cancer presented at the 2024 San Antonio Breast Cancer Symposium. The EMBER-3 trial showcased promising data for the oral SERD imlunestrant, demonstrating improved progression-free survival in combination with abemaciclib, particularly in patients with ESR1 mutations.

The 10-year update from the OlympiA trial reaffirmed the benefits of adjuvant PARP inhibitors in BRCA1/2 mutation carriers, showing long-term survival advantages. Additionally, the SOLTI VALENTINE study on the HER3-directed antibody-drug conjugate HER3-DXd revealed a robust immune response and fewer severe side effects compared with chemotherapy, offering a potential alternative for neoadjuvant therapy in high-risk early breast cancer.